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a b s t r a c t
African horse sickness virus (AHSV) VP7 is the major core protein of the virion. Apart from its role in
virus assembly, VP7 forms crystalline-like particles during infection and when expressed in insect cells.
The aim of this study was to investigate the process of VP7 crystalline-like particle formation. The
intracellular distribution of VP7 was characterized in different systems and the association of VP7 with
virus factories during AHSV infection was investigated. It was shown that the majority of VP7 is
sequestered into these particles, and is therefore not available for new virion assembly. This is likely to
have a negative impact on virus assembly and yield. By using speciﬁc markers and inhibitors of host
trafﬁcking pathways, VP7 localization was shown to be independent of host trafﬁcking mechanisms and
evaded host defenses against aggregation. Studying the process of VP7 crystalline-like particle formation
will help us further understand AHSV replication and assembly.
& 2014 Elsevier Inc. All rights reserved.
Introduction
African horse sickness (AHS) is a vector-borne disease of equids
that can cause up to 90% mortality in susceptible horses and places
a signiﬁcant economic burden on equine industries due to a
sanctioned restriction of movement of horses from affected areas
(Mellor and Hamblin, 2004). The disease is endemic in sub-
Saharan Africa, and is listed as a notiﬁable viral disease by the
World Organization for Animal Health (OIE). AHS is caused by an
orbivirus of the family Reoviridae known as African horse sickness
virus (AHSV). The virus is transmitted by the biting midge,
Culicoides imicola, and replicates efﬁciently in both insect and
mammalian hosts (Du Toit, 1944; Venter et al., 2009). The AHSV
virion is modelled after the orbivirus prototype, bluetongue virus
(BTV) – a noneveloped virus composed of two layers of proteins
that are organized into an outer capsid consisting of proteins VP2
and VP5, and an icosahedral core particle composed of major core
proteins VP7 and VP3 (Hewat et al., 1992b). The core particle
contains a genome of 10 segments of dsRNA and a transcription
complex of three minor enzymatic proteins VP1, VP4, and VP6
(Grubman and Lewis, 1992; Roy et al., 1994). During infection the
outer capsid proteins are responsible for entry into target cells,
followed by the release of the core particle into the cytoplasm
where it becomes transcriptionally active (Hassan et al., 2001;
Hassan and Roy, 1999; Huismans et al., 1987; Huismans and
Verwoerd, 1973). As infection progresses viral inclusion bodies
(VIBs), directed by non-structural protein NS2, begin to form and
act as sites for virus replication and early viral assembly (Brookes
et al., 1993; Kar et al., 2007).
VP7 forms the outer layer of the virus core particle by
assembling into trimers that attach perpendicularly to the interior
VP3 surface of the subcore. Each VP7 monomer is composed of a
top domain (formed by aa 121–249) and a bottom domain (made
up of the N- and C-terminal regions, aa 1-120 and aa 250-349
respectively). The bottom domain of VP7 trimers make contact
with the VP3 proteins, forming a precise VP7 lattice composed of
260 trimers that are deposited onto the inner VP3 scaffold that
encloses the genome and transcription complex (subcore). This
results in a stable icosahedral core particle (Basak et al., 1992;
Grimes et al., 1995, 1997, 1998; Hewat et al., 1992a; Prasad et al.,
1992). When the VP7 and VP3 genes are simultaneously expressed
in a baculovirus expression system, the proteins spontaneously
assemble into highly stable core-like particles (CLPs) (French and
Roy, 1990; Maree et al., 1998). The expression of VP3 alone forms
an unstable single-shelled subcore structure that can only be
stabilized by the addition of VP7 (Le Blois and Roy, 1993; Limn
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and Roy, 2003; Limn et al., 2000). During virus assembly, the
addition of the VP7 layer to the subcore is essential for the
stabilization and protection of the newly packaged ssRNAs and is
necessary prior to the trafﬁcking of the assembled complex out of
VIBs (Matsuo and Roy, 2013).
BTV VP7 has often been used as a model to experimentally
describe intermolecular interactions in the BTV assembly process.
However, very little is known about the process of AHSV core
assembly. BTV and AHSV VP7 have 67% similarity (Roy et al., 1994)
and are both able to spontaneously form soluble trimers when
expressed in vitro (Basak et al., 1996; Limn et al., 2000; Rutkowska
et al., 2011). Overall, the BTV VP7 protein is highly soluble and
when expressed in isolation, it assembles into soluble trimers that
are evenly distributed throughout the cell (Basak et al., 1996; Kar
et al., 2007; Monastyrskaya et al., 1997; Oldﬁeld et al., 1990). In
contrast to BTV, the AHSV VP7 is said to be highly insoluble (Basak
et al., 1996; Roy et al., 1991) and, unlike any of the cognate
orbivirus proteins, forms unique ﬂat hexagonal crystalline-like
particles when expressed either in isolation in insect cells or in
AHSV-infected cells (Burroughs et al., 1994; Chuma et al., 1992;
Venter et al., 2012). The impact of the formation of these particles
or their role during AHSV replication remains to be discovered.
The formation of these crystalline-like particles appears to limit
in vitro CLP formation by sequestering available soluble VP7
trimers and preventing them from incorporating onto the subcore
(Maree et al., 1998). Given that the majority of soluble BTV VP7 is
present in VIBs during core assembly, the sequestration of avail-
able VP7 during AHSV core assembly will likely have a negative
effect on the efﬁciency of AHSV core assembly and resulting
viral yield.
In general, many viruses induce cellular remodelling during
infection which results in the formation of similar insoluble
aggregates that generally contain viral structural proteins. These
aggregates are sometimes used by viruses to hold and accumulate
large complexes of both viral and host proteins to protect and
promote viral replication, assembly, and intracellular transporta-
tion (Kopito, 2000; Moshe and Gorovits, 2012; Wileman, 2006).
Viruses often target and exploit key stages in host regulatory
protein trafﬁcking pathways, such as cytoskeleton or aggresomal
pathways, as a means to move throughout the cytoplasm or to
generate sites for virus replication (Dohner et al., 2005; Vogel et
al., 2007). Viral factories, which are generally maintained by
microtubules and localized near the microtubule organizing center
(MTOC), often resemble aggresomes (Heath et al., 2001). Aggre-
somes are generally formed in response to cellular stress from
protein aggregation or misfolding and hold aggregated proteins in
a vimentin cage for subsequent proteasomal or autophagic degra-
dation (Ciechanover, 2005; Kopito, 2000; Wileman, 2007). Thus
the formation of these AHSV VP7 particles may, alternatively,
result from activation of host defense mechanisms that recognize
virus components and consequently sequester them into aggre-
gates which are then targeted for storage and/or degradation.
Very little is known about the process of AHSV VP7 crystalline-
like particle formation during virus infection, speciﬁcally whether
the formation of these particles is caused by interaction with host
cellular trafﬁcking pathways or defenses against viral infection or,
alternatively, whether these particles result from aggregation due
to overexpression or misfolding. Here, we aim to investigate
aspects associated with the formation of AHSV VP7 crystalline-
like particles by studying VP7 intracellular distribution in different
cell-types and expression systems. We also examine the role of
host trafﬁcking pathways and defense mechanisms in the forma-
tion of AHSV VP7 crystalline-particles. To support this study, we
used an eGFP-tagged AHSV VP7 fusion protein, designated VP7-
144-eGFP, to facilitate the tracking of the protein inside the cell.
We could show that the VP7-144-eGFP fusion protein properly
assembles into trimers and that the VP7-eGFP fusion protein
resembles the intracellular distribution of wild-type VP7, allowing
us to use it as a tool to study VP7 intracellular trafﬁcking
behaviour. We ﬁrst examined and characterized the trafﬁcking
and intracellular distribution of VP7 in both insect and mamma-
lian cells (transient expression), as well as in the presence of other
AHSV proteins (i.e. in AHSV-infected cells). We also examined the
association of VP7 with VIBs in AHSV-infected cells and found that
crystalline-like particle formation is likely to have a negative
impact on virus assembly. We then set out to determine if VP7
interacts with host trafﬁcking pathways by examining the locali-
zation of VP7 by using the VP7-144-eGFP fusion protein in
conjunction with a range of cellular markers. This was followed
by the chemical inhibition of certain trafﬁcking pathways to
examine the effect on VP7 localization and crystalline particle
formation. In this study we describe how VP7 is localized in a
manner that is inherent to AHSV VP7 itself.
Results
Identiﬁcation and characterization of wild-type AHSV VP7
and VP7-eGFP fusion protein intracellular distribution
In order to facilitate the appropriate tracking of VP7 in the cell,
we investigated whether the top domain of VP7 could be modiﬁed
with the insertion of a large foreign protein, eGFP. A VP7-eGFP
fusion protein was constructed by inserting eGFP into a multiple
cloning site in the top domain of an available AHSV VP7 vector
(Rutkowska et al., 2011) at amino acid position 144. The resulting
VP7-eGFP fusion protein, VP7-144-eGFP, was then expressed in
insect cells (Sf9 cells) using the baculovirus protein expression
system. Protein synthesis was conﬁrmed by SDS-PAGE and Wes-
tern blot analysis using anti-VP7 antibody. The size of VP7-144-
eGFP corresponded to the expected size of 68 kDa, and migrated
slower than the 38 kDa wild-type VP7 protein (Fig. 1A and B, Lanes
3 and 4). To determine whether the insertion of eGFP into the VP7
top domain disrupted VP7 assembly and stability, we investigated
its ability to form trimers by means of a modiﬁed SDS-PAGE
analysis of unboiled samples previously described for the detec-
tion of VP7 trimers (Monastyrskaya et al., 1997). As shown in
Fig. 1A and B, the 114 kDa wild-type VP7 and 204 kDa VP7-144-
eGFP multimers migrated at a slower rate than their respective 38
and 68 kDa monomeric (M) counterparts when incubated at room
temperature (RT). The presence of the high molecular weight
trimer protein bands (T) in both wild-type and fusion VP7 protein
samples conﬁrmed that VP7-144-eGFP forms trimers, similar to
wild-type VP7.
To establish the use of VP7-144-eGFP as an accurate marker for
the investigation of the intracellular distribution of AHSV VP7, we
compared the intracellular localization of VP7-144-eGFP in Sf9
cells to the localization of wild-type AHSV VP7 in recombinant
baculovirus-infected Sf9 cells and AHSV-infected BSR cells. AHSV-
infected BSR cells as well as Sf9 cells infected with recombinant
baculovirus expressing wild-type AHSV VP7 were ﬁxed at 48 h
post infection (p.i.) and immunostained with antibody against
AHSV VP7. Sf9 cells were also infected with recombinant baculo-
virus expressing the VP7-144-eGFP fusion protein and its distribu-
tion was detected following ﬁxation by eGFP auto-ﬂuorescence at
48 h p.i. using confocal microscopy (Fig. 2).
In the presence of other AHSV proteins in AHSV-infected cells
(Fig. 2A), some VP7 localized to small punctate areas within the
cytoplasm, however the majority of VP7 was concentrated as one
distinct ﬂat crystalline-like particle within each cell. In Sf9 cells,
both the recombinant baculovirus-expressed wild-type AHSV VP7
(Fig. 2B) and VP7-144-eGFP fusion protein (Fig. 2C) formed small
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punctate foci in the cytoplasm as well as a single, highly localized
structure within the cell. Upon three-dimensional reconstruction
(rendered z-stack analysis) using Zeiss LSM imaging software, the
structures formed by wild-type VP7 in Sf9 cells were found to be
ﬂat crystalline-like structures with a similar morphology to those
seen in AHSV-infected cells (Fig. 2B). Similarly, the foci formed by
VP7-144-eGFP in Sf9 cells were found to be ﬂat rigid structures
(Fig. 2C) comparable to wild-type AHSV VP7. In all instances, the
crystalline structures formed by the VP7 proteins appeared to
range in size from 2 mm to 5 mm as previously reported for the
ultrastructure of AHSV VP7 (Venter et al., 2014). The three-
dimensional stacking results from Fig. 2B (right) show that the
rectangular VP7 crystalline structures observed in Sf9 cells by
confocal microscopy (Fig. 2B) and in AHSV-infected cells pre-
viously observed by transmission electron microscopy (Venter
et al., 2014) represent the hexagonal AHSV VP7 crystals formerly
isolated from AHSV-infected cells (Burroughs et al., 1994). In
addition, these results indicate that VP7-144-eGFP fusion protein
has a similar intracellular localization to wild-type VP7, and forms
structures that represent a similar VP7 organization as the
crystalline-like structures of wild-type VP7.
Next, we investigated if the VP7 incorporated into the
crystalline-like particles co-localized with NS2, a marker for VIBs
(Kar et al., 2007). AHSV-infected BSR cells were ﬁxed and co-
labeled with anti-NS2 and anti-VP7 antibodies at various times
post infection (Fig. 3). The VP7 incorporated in the crystalline-like
particles (boxes) was not associated with VIBs, while the VP7 in
the smaller punctate foci (arrows) was associated with VIBs
(Fig. 3). The small foci therefore represent the relatively minor
amount of VP7 that is available for core particle formation during
progeny virion assembly in the VIBs, while the majority of VP7 is
packaged into crystalline-like particles and remains as crystalline-
like particles over time.
To determine whether the recombinant VP7-eGFP fusion pro-
tein behaves similarly to wild-type VP7, we investigated the
localization of VP7-144-eGFP relative to VIBs and compared it to
the localization of wild-type AHSV VP7 relative to VIBs in Sf9 cells,
in the absence of the majority of the other AHSV proteins. It has
previously been suggested that VP3 is required to recruit VP7 to
VIBs during BTV core assembly (Kar et al., 2007). We therefore
included VP3 in these experiments. Sf9 cells were co-infected with
recombinant baculoviruses expressing AHSV VP7, NS2, and VP3
(Fig. 4A) or VP7-144-eGFP, NS2, and VP3 (Fig. 4B). Cells were
incubated for 48 h, ﬁxed and VIBs were labeled with anti-NS2 and
processed for immunoﬂuorescence microscopy. In the case of cells
expressing wild-type AHSV VP7, VP7 was labeled with anti-VP7
primary antibodies while the localization of VP7-144-eGFP was
visualized based on eGFP auto-ﬂuorescence. VP3 expression was
conﬁrmed separately by labeling Sf9 cells infected with recombi-
nant baculovirus expressing VP3 with anti-VP3 primary antibody
at 48 h p.i. (data not shown). Results show that the large structures
formed by VP7-144-eGFP (boxes) do not localize with NS2, while
the smaller more diffuse concentrations of VP7-144-eGFP (arrows)
co-localized with the punctate foci of NS2 (VIBs) (Fig. 4B). A similar
pattern was observed in Sf9 cells expressing wild-type AHSV VP7
and NS2 where the crystalline-like VP7 particles (boxes) were not
associated with VIBs, while the smaller foci (arrows) localized with
VIBs (Fig. 4A). The behaviour of VP7-144-eGFP is therefore similar
to wild-type AHSV VP7 in AHSV-infected cells (Fig. 3) and in Sf9
cells expressing wild-type AHSV VP7 and NS2.
Together, these results indicate that the insertion of eGFP in the
top domain of VP7 did not substantially affect the normal target-
ing, localization, or behaviour of AHSV VP7. VP7-144-eGFP could
therefore be used as a tool to study AHSV VP7 trafﬁcking in
the cell.
Comparison of the intracellular distribution and trafﬁcking of fusion
protein VP7-144-eGFP in insect and mammalian cells
To gain a better understanding of the manner in which VP7 is
trafﬁcked to form these crystalline-like particles, we compared the
intracellular distribution of baculovirus expressed VP7-144-eGFP
in insect cells to that of transiently expressed VP7-144-eGFP in
mammalian cells at various times. This would enable us to
determine if the distribution of AHSV VP7 is cell-type speciﬁc,
and to establish whether the high level of protein expression
inherent to baculovirus expression systems in insect cells affects
the normal localization and trafﬁcking of VP7. To transiently
Fig. 1. Expression and trimerization assay of wild-type (WT) VP7 and VP7-144-eGFP proteins. Sf9 cells were infected with recombinant baculovirus expressing either
WT-VP7 or VP7-144-eGFP. Cells were harvested at 48 h p.i., lysed, and assayed for trimer formation. Coomassie blue-stained SDS-PAGE (A) and Western blot using anti-VP7
antibodies (B) proﬁles of boiled (95 1C) and unboiled (RT) VP7 samples. The WT and fusion proteins are indicated. The positions of VP7 monomers (M) and trimers (T) are
indicated. The doublets observed in lanes 5 and 6 indicate the instability of trimers in the presence of SDS at RT.
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express the VP7-144-eGFP fusion protein in mammalian cells, the
VP7-144-eGFP gene was cloned into a mammalian expression
vector. Plasmid containing the VP7 fusion protein was then
transfected into BSR cells using Lipofectamine2000 (Life Technol-
ogies) until the optimal concentration (0.8 mg) was determined
by analysis of auto-ﬂuorescence in live cells using confocal
microscopy.
The distribution of VP7 over time was examined and compared
in both insect and mammalian cells. Sf9 cells were infected with
recombinant baculovirus expressing VP7-144-eGFP, and BSR cells
were transfected with plasmid expressing VP7-144-eGFP fusion
protein. Cells were incubated and visualized by immunoﬂuores-
cence microscopy (ﬁxed or unﬁxed) at a variety of times (ranging
from 12 h to 72 h) post infection (p.i.) or post transfection (p.t.) to
determine the kinetics of protein expression for each system
(Fig. 5). The protein was initially homogenously distributed
throughout the cytoplasm in both insect and mammalian cells
(24 h p.i. and 36 h p.t. respectively), after which the VP7 distribu-
tion became less diffuse and organized into multiple foci through-
out the cytoplasm. As time progressed, the foci became less
numerous and grew in size, after which they coalesced to one
site alongside the nucleus to ﬁnally form the characteristic VP7
crystalline-like particle (48 h p.i. and 68 h p.t.). This intracellular
distribution was not observed when eGFP was expressed alone,
as eGFP was evenly distributed throughout the cell from 12 to 72 h
p.i./p.t. in both Sf9 and BSR cells (data not shown). To eliminate
Fig. 2. Intracellular distribution of VP7 within AHSV- and recombinant baculovirus infected cells by confocal microscopy. (A) BSR cells infected with AHSV-4 and ﬁxed at 48 h
p.i. Magniﬁed hexagonal VP7 crystalline-like particle is depicted on the right. (B) Sf9 cells infected with recombinant baculovirus expressing wild-type AHSV VP7 and ﬁxed at
48 h p.i. Magniﬁed three-dimensional reconstruction (rendered z-stack analysis) of crystalline-like particles (arrows) is shown on the right. (C) Sf9 cells infected with
recombinant baculovirus expressing fusion protein VP7-144-eGFP, ﬁxed at 48 h p.i. with reﬁned and magniﬁed image to the right. VP7 in A-B was detected with anti-VP7
antibody (guinea pig) and FITC conjugated secondary antibody (green). VP7 in C was visualized based on eGFP auto-ﬂuorescence. Nuclei were stained with DAPI (blue). Scale
bars represent 10 mm (panels to the left) and 2 mm in magniﬁed images (panels to the right).
S. Bekker et al. / Virology 456-457 (2014) 279–291282
artefacts that might arise from ﬁxation of cells, unﬁxed live cells
were also examined and similar ﬂuorescent signals were visible in
both insect and mammalian cells (Fig. 5 A and B bottom panels).
The data obtained thus far conﬁrmed that the ability of VP7 to
assemble into these large particles was not dependent on cell-type
speciﬁc factors, since similar VP7 particles and intracellular
distribution were observed in both insect and mammalian cells
when VP7 was expressed by different systems (AHSV infection,
recombinant baculovirus infection, and plasmid transfection). In
addition, the diffuse distribution of VP7 at early times post
infection indicated that AHSV VP7 was in fact expressed as a
soluble protein, after which the protein was transported in the cell
to coalesce and form an insoluble crystalline particle.
AHSV VP7 intracellular distribution and trafﬁcking is not dependent
on general host cell transport or defense mechanisms
We subsequently set out to determine if the crystalline struc-
tures formed by AHSV VP7 in infected and transfected cells coalesce
as a result of interaction with host trafﬁcking pathways and defense
mechanisms. In each experiment, recombinant baculovirus-infected
Sf9 cells expressing VP7-144-eGFP or BSR cells transfected with
plasmid expressing VP7-144-eGFP were labeled with antibodies
against speciﬁc cellular components in the presence or absence of
the corresponding cellular transport-inhibiting drug. Cells were
examined at times of active VP7 transport to multiple foci (24 h
p.i. or 48 h p.t.) as well as at times of large crystalline-like particle
formation (48 h p.i. or 68 h p.t.). The effects of the drug on the
evolution and intracellular localization of VP7 particles was then
visualized using confocal microscopy.
VP7 crystalline-like particle formation is not dependent on the
microtubule network
To investigate the role of the microtubule network on the
migration of VP7, cells were treated or not with colchicine,
a microtubule depolymerizing drug, and subsequently labeled
with anti-tubulin antibody. In pilot experiments using tubulin
staining, we found that treatment of cells with colchicine at a
concentration of 10 mM was sufﬁcient to depolymerize the cellular
microtubules. Cells expressing VP7-144-eGFP were treated or not
with colchicine from the beginning of infection or transfection to
time of ﬁxation. Comparison of the untreated and treated cells
(Fig. 6) showed that in spite of the microtubules being completely
depolymerized at key points during expression, this did not cause
a signiﬁcant change in the size, morphology, intracellular distribu-
tion, or migration of VP7 in insect or mammalian cells (Fig. 6
bottom panel). These results established that VP7 foci are not
positioned at the MTOC, and that transport along microtubules is
not required for the formation of VP7 particles.
Fig. 3. Association of VP7 foci and crystalline-like particles with VIBs in AHSV-infected BSR cells at various times post infection by confocal microscopy. BSR cells were
infected with AHSV-4 and ﬁxed at 8 h, 12 h, and 24 h p.i. VP7 was detected with anti-VP7 primary antibody (guinea pig) and FITC conjugated secondary antibody (green),
NS2 was detected with anti-NS2 primary antibody (rabbit) and Alexa Fluor 633 conjugated goat anti-rabbit secondary antibody (red). Nuclei were stained with DAPI (blue).
Scale bars represent 10 mm.
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VP7 is not contained within or associated with the aggresomal
pathway
Next, we sought to determine if the particles formed by VP7 in
cells expressing VP7-144-eGFP were associated with aggresomes.
Since aggresomes induce the redistribution of vimentin to form a
cage-like structure around the aggregated protein, we labeled
vimentin in order to determine if VP7 was contained within an
aggresome. BSR cells were transfected with plasmid expressing
VP7-144-eGFP and labeled with anti-vimentin. Labeling in Sf9
cells was not possible as antibodies for insect cell vimentin are
unavailable. Results from Fig. 7A illustrate that vimentin is not
redistributed to form a cage around the VP7 structure, and VP7
does not associate with vimentin. To conﬁrm this ﬁnding, vimen-
tin was disrupted in both recombinant baculovirus-infected Sf9
and transfected BSR cells using acrylamide (ACR), a drug that
speciﬁcally disrupts the vimentin intermediate ﬁlament network
(Fig. 7A and B) (Bhattacharya et al., 2007). In preliminary experi-
ments cells were treated at various times and with various
concentrations of ACR in order to obtain viable cells that had
disrupted vimentin (conﬁrmed by vimentin-labeling of treated
cells). Cells were treated with 5 mM ACR at 24 h prior to ﬁxation,
as well as for the full period following infection or transfection.
The disruption of vimentin did not have an effect on VP7
intracellular distribution in BSR (Fig. 7A bottom panel) and Sf9
cells (Fig. 7B). Aggresomes are commonly known to recruit
misfolded proteins by the enzyme, Histone Deacetylase 6 (HDA6)
(Kawaguchi et al., 2003). In order to determine if VP7 is misfolded
in any way, cells were treated with Scriptaid, a Histone deacetylase
6 inhibitor. If VP7 is misfolded and targeted for aggresome
formation, the inhibition of HDA6 would have an effect on the
trafﬁcking behaviour and the subsequent subcellular localization
of VP7. Cells expressing VP7-144-eGFP were incubated in the
presence of 5 mM Scriptaid according to conditions established
previously (Beaudoin et al., 2008) and ﬁxed at 48 h p.i. Results
showed that the inhibition of HDAC 6 had no effect on VP7
trafﬁcking or intracellular distribution (Fig. 7B). The same results
were observed when transfected BSR cells expressing VP7-144-
eGFP were treated with 5 mM Scriptaid (data not shown). These
data and the lack of vimentin redistribution suggest that the
particles formed by VP7-144-eGFP are not misfolded aggregates,
and are not contained within an aggresome.
VP7 is not targeted for degradation by the host cell
When a foreign protein is expressed in a cell, that protein is
often targeted for degradation by the ubiquitin–proteasome sys-
tem (UPS) or the lysosomal pathway. In order to investigate the
potential role of the UPS in VP7 distribution and crystalline-like
particle formation, the 26 S proteasome as well as ubiquitin were
stained and their association with VP7-144-eGFP was examined in
insect and mammalian cells using confocal microscopy (Figs. 8 and 9).
Results show that the large VP7 foci were not made up of
ubiquinated protein (Figs. 8 and 9A), and do not co-localize with
the proteasome (Figs. 8 and 9A). To conﬁrm that VP7 was not
associated with the proteasome, MG132 (a potent proteasome
inhibitor) was also used. After treatment with a range of MG132
concentrations, both baculovirus-infected Sf9 and transfected BSR
cells were treated with 100 mM of MG132 at 24 h p.i. or p.t. for
optimal proteasomal inhibition. When the proteasome was inhib-
ited, VP7 foci formation was not affected in either Sf9 or BSR cells
(Figs. 8 and 9C). These results conﬁrm that VP7 is not associated
with the UPS.
The association of VP7 with lysosomes was examined by
labeling lysosomes in Sf9 and BSR cells expressing VP7-144-eGFP
using Lysotracker Red Dye (Life Technologies). There was no
association of VP7 foci with the lysosome in either cell type
Fig. 4. Association of wild-type VP7 and VP7-144-eGFP with NS2 in the presence of VP3 in Sf9 cells. (A) Sf9 cells were co-infected with recombinant baculoviruses
expressing AHSV NS2, VP3, and wild-type VP7 (A) or NS2, VP3 and VP7-144-eGFP (B) at a MOI of 10. Cells were ﬁxed at 48 h p.i. and labeled with anti-NS2 antibody (rabbit)
and Alexa Fluor 633 conjugated anti-rabbit secondary antibody (red). (A) VP7 was detected with anti-VP7 (guinea pig) primary antibody and FITC conjugated secondary
antibody (green). (B) VP7-144-eGFP was visualized based on eGFP auto-ﬂuorescence. Nuclei were stained with DAPI (blue). Scale bars represent 10 mm.
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(Figs. 8 and 9D) suggesting that VP7 did not use the lysosomal
pathway at any stage during VP7 crystalline particle formation.
Discussion
In this study, we have addressed questions associated with the
way in which AHSV VP7 is localized in both insect and mammalian
cells. We examined the nature of AHSV VP7 crystalline particle
formation in order to gain a better understanding of the behaviour
of AHSV VP7 during core particle assembly. The protein was found
to assemble into distinct ﬂat crystalline-like particles in the
presence or absence of other AHSV proteins, and localizes in this
fashion independently of the investigated host cellular machinery.
Furthermore, the formation of these crystalline-like particles
sequesters the majority of VP7 during core assembly. This study
offers new insights into the mechanism of AHSV assembly.
The intracellular distribution and trafﬁcking behaviour of a
VP7-eGFP fusion protein were examined by immunoﬂuorescence
microscopy at various times post infection. We found that VP7 is
initially trafﬁcked into numerous foci throughout the cytoplasm.
With time, these foci migrate and coalesce to form one or more
large crystalline-like particles within the cell. To determine if
localization was cell-type speciﬁc, experiments were performed
in both insect and mammalian cell types. Very similar results were
found for both systems, however the large crystalline-like particles
of transiently expressed VP7 in mammalian cells were observed at
a later time post transfection (68 h p.t.). This delay was most likely
due to the lower level of protein expression inherent in transient
systems. It has been suggested that crystalline particle formation is
a side-effect of AHSV VP7 over-expression in the baculovirus
expression system resulting in aggregation of the insoluble pro-
tein. Our data illustrates that the formation of VP7 crystalline-like
particles is not caused by over-expression, as the transient expres-
sion of VP7 in BSR cells as well as VP7 synthesis in AHSV-infected
BSR cells yielded VP7 that assembled into crystalline-like particles.
By investigating the interaction of VP7 with cellular trafﬁck-
ing pathways, we showed that VP7 manages to evade the host
Fig. 5. Intracellular distribution of VP7-144-eGFP fusion protein in recombinant baculovirus-infected Sf9 and transfected BSR cells at indicated times. Sf9 cells (A) and BSR
cells (B) expressing VP7-144-eGFP were visualized by confocal microscopy either ﬁxed (top panel) or unﬁxed (live) (bottom panel) in each case at the indicated times. Nuclei
were stained with DAPI (blue). Scale bars represent 10 mm.
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cell defenses against protein aggregation and crowding. VP7
particle formation was not related to mechanisms of aggresome
generation, the ubiquitin–proteasome system, or lysosomal
pathways. In addition the results indicate that VP7 crystalline-
like particles are not misfolded aggregates, as proteins that are
misfolded are typically targeted to the aggresome by histone
deacetylase 6. These data imply that VP7 crystalline particle
formation is not necessarily a by-product of its innate insolubi-
lity and subsequent aggregation, but rather a reﬂection of a
highly ordered process in which VP7 self-assembly takes place
during core assembly.
We have shown that VP7 trafﬁcking and crystalline-like parti-
cle formation are independent of other AHSV proteins, and of host
transport and trafﬁcking machinery investigated here. Thus, the
unique trafﬁcking behaviour and the ability of VP7 to form
crystalline-like particles are likely to be driven by factors that
occur within or are inherent to VP7 itself, i.e. by a process of VP7
self-assembly. Speciﬁcally, when VP7 is expressed, it forms trimers
in solution (seen by the homogenous distribution of VP7 at the
initial stages of expression). These trimers have an inherent
afﬁnity for one another through their very strong and very speciﬁc
side-to-side trimer–trimer interactions (Limn and Roy, 2003).
These trimer–trimer interactions are what drive the formation of
small foci at the intermediate stages of expression, as well as the
coalescence of these foci to form crystalline-like particles at later
stages of expression. Capsid proteins of a number of viruses have
been shown to self-assemble into a variety of particles or struc-
tures (Bancroft et al., 1967; Salunke et al., 1986; Volpers et al.,
1994). The capsid protein VP6 of rotavirus has been shown to self-
assemble into spherical and helical particles which are dependent
on pH conditions, implying that the charge of certain residues
within the protein is responsible for self-assembly (Lepault et al.,
2001).
It is important to note that it is not trimer formation that drives
core assembly, but rather the interactions between trimers that
allow VP7 trimers to self-associate and form the VP7 lattice. Limn
and Roy (2003) suggest that during core assembly, multiple sheets
of BTV VP7 may form at different sites and that lattice formation
does not result from trimers loosely associating at one point on
VP3. Here we suggest that the VP7 crystalline particles are
products of multiple sheets of AHSV VP7 trimers coming together
to form highly ordered structures as a result of very strong trimer–
trimer interactions in the presence or absence of VP3. Interest-
ingly, BTV VP7 trimers do not form any morphological entities
without the presence of VP3 (Kar et al., 2007; Loudon and Roy,
1991); and the formation of a stable BTV VP7 lattice in BTV core
assembly requires attachment to the BTV VP3 subcore (Limn and
Roy, 2003). This suggests that BTV VP7 trimer–trimer interactions
are weaker than those of AHSV VP7 trimers, and AHSV VP7
crystalline-like particle formation appears to be a by-product of
inherently strong AHSV VP7 trimer–trimer interactions.
Despite the high level of conservation of VP7 across orbiviruses,
it is puzzling that AHSV VP7 behaves in such a unique manner.
Viruses are often under selective pressures and genome segments
of dsRNA viruses have been shown to evolve independently from
one another. Here we show that a large majority of the synthe-
sized VP7 is channelled into these crystalline particles during
AHSV assembly. Given the negative effects of aggregation into
particles with regards to core assembly and replication rate, it is
unclear why the virus would retain this seemingly undesirable
feature. To speculate, the crystalline particles may contribute to
virus pathogenesis as formation of these crystalline particles could
be detrimental to cellular function and membrane integrity. None-
theless, it is unclear whether VP7 aggregation into these particles
is to the beneﬁt or detriment to the virus. Here we show that the
formation of crystalline particles is driven by factors inherent to
the VP7 protein itself. The next step will be to determine what
properties of VP7 drive self-assembly, and to examine the role of
VP7 self-assembly in core formation and virus replication. To
address this topic, we have used a bioinformatics approach to
identify VP7 residues that are responsible for trimer–trimer
interactions. By targeting these residues for mutation, we will be
able to establish the role of AHSV trimer–trimer interactions in
VP7 crystalline particle formation and through a reverse genetics
approach we will be able to ascertain the role of crystalline
particles in virus replication.
Fig. 6. VP7 is not associated with microtubules in insect and mammalian cells. Sf9 cells were mock infected or infected with recombinant baculovirus expressing VP7-144-
eGFP and ﬁxed at 48 h p.i. BSR cell monolayers were mock transfected or transfected with VP7-144-eGFP mammalian expression vector, and ﬁxed at 68 h p.t. Cells were
untreated (top panel), or treated with 10 mM colchicine from 0 to 48 h p.i. (Sf9 cells) or 0 to 68 h p.t. (BSR cells) (bottom panel). Cells were immunostained with mouse
monoclonal anti-tubulin primary antibody followed by Alexa Fluor 594 conjugated goat anti-mouse IgG (red). VP7-144-eGFP was visualized based on eGFP auto-ﬂuorescence
(green). Nuclei were stained with DAPI (blue). Scale bars represent 10 mm.
S. Bekker et al. / Virology 456-457 (2014) 279–291286
We have demonstrated that VP7, although inherently present
in high abundance when expressed intracellularly, manages to
evade host cell defenses against protein aggregation, over-expres-
sion, and presence of foreign protein. During the ﬁrst stages of
replication the newly released core protects the viral genome and
enzymes within from host defenses. Furthermore, the addition of
VP7 onto the subcore during core assembly may be necessary prior
to the trafﬁcking of the core out of VIBs (Matsuo and Roy, 2013).
These putative roles of core protein VP7 may offer an explanation
for its ability to evade host defenses and it would therefore be
expected that VP7, which forms the outer layer of the core particle,
possesses the ability to remain a highly stable outer core layer
capable of protecting the subcore within from host cell defenses
against invasion.
Materials and methods
Cells and viruses
Spodoptera frugiperda (Sf9) cells were maintained at 27 1C in
suspension or monolayer cultures in TC-100 insect medium
(Sigma) with nonessential amino acids (Highveld Biological)
supplemented with 10% fetal calf serum (FCS) and the appropriate
antibiotics (penicillin, streptomycin, and fungizone). Recombinant
baculoviruses were generated using the Bac-to-Bac Baculovirus
expression system (Life Technologies) and were propagated in Sf9
cells. Recombinant plaque-puriﬁed baculoviruses, capable of
expressing wild-type AHSV-9 VP7; wild-type AHSV-9 VP3; wild-
type AHSV-9 NS2; and eGFP in Sf9 cells were available at the start
Fig. 7. VP7 is not associated with the aggresomal pathway. (A) BSR monolayers were mock transfected or transfected with VP7-144-GFP mammalian expression vector and
incubated in the absence (top panel) or presence (bottom panel) of 5 mM acrylamide. Acrylamide (5 mM) was added to medium 24 h prior to ﬁxation. Cells were ﬁxed at
68 h p.t. and vimentin was stained with mouse monoclonal antibody against vimentin followed by Alexa Fluor 594 conjugated goat anti-mouse IgG (red). VP7-144-eGFP was
visualized based on GFP auto-ﬂuorescence (green). Nuclei were stained with DAPI (blue). (B) Sf9 cells were infected with recombinant baculovirus expressing VP7-144-eGFP
and incubated in the presence of 5 mM acrylamide or 5 mM Scriptaid from 0 to 48 h p.i. VP7-144-eGFP was visualized based on GFP auto-ﬂuorescence (green). Nuclei were
stained with DAPI (blue). Scale bars represent 10 mm in (A) and 100 mm in (B).
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Fig. 8. VP7 is not associated with the ubiquitin–proteasome system or the lysosomal pathway in insect cells. Sf9 cells were infected with recombinant baculovirus expressing
VP7-144-eGFP, ﬁxed at 48 h p.i., and labeled using antibodies against ubiquitin (mouse) (A) or the 26 S proteasome (rabbit) (B) followed by Alexa Fluor 594 conjugated goat
anti-mouse IgG or Alexa Fluor 633 conjugated goat anti-rabbit IgG (red) respectively. To inhibit the proteasome, cells expressing VP7-144-eGFP were incubated in the
presence of 100 mM MG132 24 h prior to ﬁxation followed by the staining of the 26 S proteasome (C). Lysosomes were labeled using Lysotracker Red Dye (Life Technologies)
(D). Scale bars represent 10 mm.
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Fig. 9. VP7 is not associated with the ubiquitin–proteasome system or the lysosomal pathway in mammalian cells. BSR cells were transfected with VP7-144-eGFP
mammalian expression vector and ﬁxed at 68 h p.t. Cells were labeled with antibodies against ubiquitin (mouse) (A) or the 26 S proteasome (rabbit) (B) followed by Alexa
Fluor 594 conjugated goat anti-mouse IgG or Alexa Fluor 633 conjugated goat anti-rabbit IgG (red) respectively. To inhibit the 26 S proteasome, transfected cells were
incubated in the presence of 100 mM MG132 24 h prior to ﬁxation followed by the staining of the 26 S proteasome (C). Lysosomes were labeled using LysoTracker Red Dye
(Life Technologies) (D). Scale bars represent 5 mm.
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of the experiment (Maree et al., 1998; Rutkowska et al., 2011;
Uitenweerde et al., 1995). BSR cells, a derivative of baby hamster
kidney (BHK) cells, were maintained in monolayers in Minimal
Essential Medium (MEM) with nonessential amino acids (Highveld
Biological) supplemented with 5% FCS and antibiotics (penicillin,
streptomycin, and fungizone) (Highveld Biological) at 37 1C in the
presence of 5% CO2. AHSV-4 was propagated in BHK cells and the
titre was determined by plaque assay in BSR cells.
Construction of pFb-VP7-144-eGFP and generation of recombinant
baculovirus for expression in insect cells
To construct a VP7-eGFP fusion protein, we inserted the eGFP
gene into the EcoRI and XhoI restriction endonuclease (R. E.) sites
of a previously constructed modiﬁed AHSV-9 VP7 vector, pFb-VP7-
144(P2) (Rutkowska et al., 2011). The pFb-VP7-144(P2) vector is a
pFastbac 1 plasmid that contains a modiﬁed AHSV-9 VP7 gene
with an insertion of 18 nucleotides comprising R. E. recognition
sites for SmaI, EcoRI, and XhoI at position 431-432 which results in
a peptide insertion of PGEFLE downstream of amino acid position
144 in the AHSV-9 VP7 top domain. To insert the eGFP gene at the
144 amino acid site, primers that were ﬂanked with EcoRI
(forward) and XhoI (reverse) R. E. sites were used to amplify the
eGFP gene from a pGEM-Teasy-eGFP plasmid (supplied by Prof. J.
Theron, University of Pretoria, Department of Microbiology). The
pFb-VP7-144(P2) vector was simultaneously digested with EcoRI
and XhoI restriction endonucleases, and the eGFP amplicon was
inserted by directional cloning. Recombinant baculoviruses were
generated as described previously (Rutkowska et al., 2011).
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot
analysis
Sf9 monolayers were infected with recombinant baculovirus
using a multiplicity of infection (MOI) of 5–10 and incubated at
27 1C. Cells were harvested at 48 h post infection, washed with
phosphate-buffered saline (PBS), and lysed at 4 1C in lysis buffer
(10 mM Tris–HCl [pH 8.0], 50 mM EDTA, 10 mM NaCl, 0.5% [v/v]
Nonidets P-40). Samples were then suspended in 6.6 ml of 3 
protein dissociation buffer (10% [v/v] β-mercaptoethanol, 4% (w/v)
SDS, 20% (v/v) glycerol, 125 mM Tris–HCl [pH 6.8], and 0.002%
(w/v) bromophenol blue) and either boiled at 95 1C or incubated at
room temperature (for identiﬁcation of trimers) (Monastyrskaya et
al., 1997) for 5 min and resolved by 12% SDS-PAGE, followed by
staining with Coomassie brilliant blue. For Western blot analysis,
proteins from SDS-PAGE gels were transferred to a Hybond
nitrocellulose membrane (Amersham) by standard blotting proce-
dures. Membranes were incubated in buffer with anti-VP7 (guinea
pig) primary antibody. Peroxidase-conjugated Protein A (ICN) was
used for detection.
Construction of pcDNA™3.2/V5-DEST-VP7-144-eGFP mammalian
expression vector for transient expression in mammalian cells
In order to express the VP7-144-eGFP fusion protein in mam-
malian cells, the polymerase chain reaction (PCR) was used to
amplify the full-length VP7-144-eGFP gene from the pFb-VP7-144-
eGFP plasmid. The PCR product was adenylated and subcloned
(using TA cloning) in pCRs8/GW/TOPOs entry vector (Life Tech-
nologies) according to the manufacturer's instructions. The VP7-
144-eGFP gene was then recombined into the mammalian expres-
sion vector, pcDNA™3.2/V5-DEST (Life Technologies) by means of
LR recombination (Gateways). The authenticity of each construct
was conﬁrmed by DNA sequencing. The mammalian expression
vector, pcDNA™3.2/V5-DEST-VP7-144-eGFP was used for transient
VP7-144-eGFP expression in BSR cells.
Transfection of BSR cells
For the transient expression of VP7-144-eGFP in mammalian
cells, 2.2105 cells were seeded the day before transfection in 24-
well plates (2 cm2 per well) containing 8 mm round glass cover-
slips. A total of 0.8 mg of pcDNA™3.2/V5-DEST-VP7-144-GFP vector
DNA was transfected into BSR cells using 2 ml of Lipofecta-
mine2000 (Life Technologies) in serum-free MEM as suggested
by the manufacturer. Transfected cells were incubated at 37 1C for
12–68 h depending on the experiment. Protein expression was
examined and conﬁrmed based on eGFP auto-ﬂuorescence using a
Zeis LSM 510 Meta confocal microscope.
Antibodies and pharmacological reagents
Primary antibody against AHSV-4 VP7 (guinea pig) and NS2
(rabbit) were available at the start of this investigation (Rutkowska
et al., 2011; Uitenweerde et al., 1995). Mouse monoclonal primary
antibodies against β-tubulin (clone TUB 2.1), vimentin (clone V9)
as well as the IgG conjugated to FITC (anti-guinea pig) secondary
antibody were obtained from Sigma. Mouse monoclonal primary
antibody against ubiquitin (clone Ubi-1) and rabbit polyclonal
antibody against 26 S proteasome were obtained from Thermo
Scientiﬁc. LysoTracker Red Dye and IgG conjugated to Alexa Fluor
594 (mouse) or Alexa Fluor 633 (rabbit) were purchased from
Molecular Probes (Life Technologies). DAPI (40,6-Diamidine-20-
phenylindole dihydrochloride) was purchased from Roche. For
pharmacological experiments, colchicine, acrylamide, MG132,
and Scriptaid were obtained from Sigma.
Immunoﬂuorescence microscopy
Cell monolayers were grown on sterile glass coverslips in 24-
well plates. Sf9 monolayers were infected with recombinant
baculovirus at a MOI of 10 and incubated at 27 1C for 24–48 h
before being ﬁxed in a 1:1 methanol:acetone solution at 4 1C for
5 min. BSR monolayers were transfected with plasmid DNA as
described above, and incubated at 37 1C for 48–68 h and ﬁxed for
30 min at room temperature with 4% (w/v) paraformaldehyde
(PFA) in PBS. Cover slips were then incubated for 15 min at room
temperature with 0.5% Triton X-100 in PBS to permeabilize the
cells. For labeling experiments, Sf9 and BSR cells were blocked in
5% blocking solution (5% milk powder in PBS) directly after
ﬁxation followed by incubation with primary antibodies for 1 h.
The cells were washed three times with wash buffer (0.5% (v/v)
Tween20 in PBS) and incubated for 1 h with appropriate second-
ary antibodies conjugated to FITC (green), Alexa Fluor 594 (red), or
Alexa Fluor 633 (red). Cells were washed again (as above) and
stained with 10 mg/ml DAPI in 1% blocking solution for 10 min.
For direct immunoﬂuorescence experiments, cells were stained
with DAPI directly after ﬁxation. Cells were washed once with PBS
before being mounted onto glass slides using VECTASHIELD
Mounting Medium (Vector Laboratories). Slides were then viewed
using a Zeiss LSM 510 Meta confocal microscope and images were
obtained using Zeiss LSM Image Browser Version 4.2.0.121.
Treatment of Sf9 and BSR cells with transport inhibitors
Sf9 cells were infected with recombinant baculovirus at MOI of
10 or BSR cells were transfected as described above. Fresh medium
containing either 10 mM colchicine, 5 mM acrylamide, 100 mM
MG132, or 5 mM scriptaid was added to the cells at indicated
times post infection or transfection. After incubation, cells were
ﬁxed and processed for immunoﬂuorescence as described above.
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